A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

IndraLab

Statements

databases
phosphosite cbn pc11 biopax bel_lc signor biogrid tas lincs_drug hprd trrust | geneways tees isi trips rlimsp medscan sparser reach
reading

BRAF binds TP53 and KRAS. 7 / 7
| 7
sparser
"TP53, KRAS , and BRAF mutations were additionally independently associated with poor prognosis, although the association with BRAF and KRAS was restricted to MSI-negative tumours."
sparser
"CRC molecular features including MSI, CIMP and mutations in BRAF , KRAS and TP53 were not associated with age-adjusted cRTL or cRTL:nRTL ratios (multivariate P>0.115 for all comparisons) (Table xref )."
sparser
"However, p53, B-Raf V600E and K-Ras G13D proved dispensable for drug’s cytotoxic activity, thus rendering 3-BrPA a powerful therapeutic tool for the successful management of urothelial bladder tumors carrying either wild-type or mutant p53, B-Raf or K-Ras oncogenic forms."
sparser
"TP53, BRAF, and KRAS mutations are associated with differential lncRNA expression."
sparser
"For example, P53, KRAS, or BRAF mutations in metastatic colorectal cancer did not associate with bevacizumab-chemotherapy treatment outcome in metastatic colorectal cancer [ xref ]."
sparser
"In multivariable analysis incorporating known clinicopathological prognostic factors, we showed that low overall mutation burden and mutations in KRAS, BRAF , and TP53 were independently associated with decreased relapse-free survival after colorectal cancer treated with curative intent."
sparser
"Furthermore, mutations in p53, K-Ras and BRAF are associated with the neoplastic changes of IECs during the sporadic colon cancer development; BRAF and K-Ras mutations have been considered as prognostic markers for MSI ( xref )."